CLINICAL TRIAL: TWO DOSES OF GW433908/RITONAVIR GIVEN WITH ABACAVIR/LAMIVUDINE C

临床试验：两剂 GW433908/利托那韦与阿巴卡韦/拉米夫定 C 联用

• 批准号: 7716816
• 负责人: DAVID A WOHL
• 金额: $ 0.15万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-02 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7716816
• 关键词: Amprenavir; Blood; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Dose; Funding; Grant; HIV-Associated Lipodystrophy Syndrome; Institution; Lamivudine; Measures; Pharmaceutical Preparations; Purpose; Research; Research Personnel; Resources; Ritonavir; Safety; Signs and Symptoms; Source; T-Lymphocyte; Time; United States National Institutes of Health; abacavir; fosamprenavir

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purposes of this study are: 1) to find out if taking fosamprenavir with 100 mg RTV plus ABC/3TC FDC is as effective as taking fosamprenavir with 200 mg RTV plus ABC/3TC FDC; 2) to measure T-cells; 3) to collect information on the safety of the two treatments; 4) to assess the physical signs and symptoms of lipodystrophy syndrome; 5) to measure the amounts of amprenavir in blood at certain time points to find out if medication has been taken correctly.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 本研究的目的是： 1) 确定服用 fosamprenavir 100 mg RTV 加 ABC/3TC FDC 是否与服用 fosamprenavir 200 mg RTV 加 ABC/3TC FDC 一样有效； 2) 测量T细胞； 3）收集两种治疗的安全性信息； 4) 评估脂肪营养不良综合征的体征和症状； 5）在特定时间点测量血液中安普那韦的含量，以了解是否正确服用药物。